Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.5977
+0.0522 (9.57%)
At close: Jul 24, 2025, 4:00 PM
0.5968
-0.0009 (-0.15%)
After-hours: Jul 24, 2025, 7:56 PM EDT

Company Description

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.

The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A.

Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017.

The company was incorporated in 1995 and is headquartered in Richmond, California.

Sangamo Therapeutics, Inc.
Sangamo Therapeutics logo
CountryUnited States
Founded1995
IPO DateApr 6, 2000
IndustryBiotechnology
SectorHealthcare
Employees183
CEOAlexander Macrae

Contact Details

Address:
501 Canal Blvd
Richmond, California 94804
United States
Phone510 970 6000
Websitesangamo.com

Stock Details

Ticker SymbolSGMO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001001233
CUSIP Number800677106
ISIN NumberUS8006771062
Employer ID68-0359556
SIC Code2836

Key Executives

NamePosition
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.Chief Executive Officer, President and Director
Scott B. WilloughbySenior Vice President, Chief Legal Officer and Corporate Secretary
Dr. Nathalie Dubois-Stringfellow Ph.D.Senior Vice President and Chief Development Officer
Gregory Davis Ph.D.Head of Research and Technology
Louise WilkieHead of Global Corporate Communications and Investor Relations
Phillip RamseyChief Technical Officer
Stephanie J. Seiler CLPVice President and Head of Business Development and Alliance Management
David OjalaScientist II - Discovery and Translational Research

Latest SEC Filings

DateTypeTitle
Jun 24, 20258-KCurrent Report
Jun 16, 20258-KCurrent Report
May 13, 2025424B5Filing
May 13, 20258-KCurrent Report
May 13, 2025FWPFree Writing Prospectus
May 12, 2025SCHEDULE 13G/AFiling
May 12, 202510-QQuarterly Report
May 6, 20258-KCurrent Report
Apr 30, 2025ARSFiling
Apr 30, 2025DEF 14AOther definitive proxy statements